Abstract
The manufacture of a diverse array of chemicals is now possible with biologically engineered strains, an approach that is greatly facilitated by the emergence of synthetic biology. This is principally achieved through pathway engineering in which enzyme activities are coordinated within a genetically amenable host to generate the product of interest. A great deal of attention is typically given to the quantitative levels of the enzymes with little regard to their overall qualitative states. This highly constrained approach fails to consider other factors that may be necessary for enzyme functionality. In particular, enzymes with physically bound cofactors, otherwise known as holoenzymes, require careful evaluation. Herein, we discuss the importance of cofactors for biocatalytic processes and show with empirical examples why the synthesis and integration of cofactors for the formation of holoenzymes warrant a great deal of attention within the context of pathway engineering.
Introduction
Synthetic biology permits the engineering of biological devices or systems with novel or enhanced functions (Church et al., ). Such an approach has numerous applications, most notably in the manufacture of a diverse number of molecules including household chemicals, biofuels, and pharmaceutical drugs (Keasling, ). This is principally achieved through pathway engineering in which enzyme activities are carefully coordinated to generate the product of interest. Approaches based on the activities of isolated enzymes (in vitro) or whole cells (in vivo) can be employed for this purpose (Guterl et al., ; Stephanopoulos, ). The latter approach in particular offers a significant benefit with respect to complex, multi-step pathways that rely on secondary cellular factors, as well as additional pathway processing. Since the enzymes serve as the workhorse components of these biocatalytic systems, both their quantitative levels and qualitative states are important parameters to consider for pathway engineering. A great deal of focus is typically placed on the quantitative levels of the enzyme (Zelcbuch et al., ) with little attention given to their overall qualitative states. Thus, the assumption is usually made that these enzyme components are functioning at full capacity. However, this may not always be the case given that a large subset of enzymes depend on cofactors for functionality.
Significance of Cofactors in Biology
All biological organisms possess a network of pathways that lead to the production of metabolites with an array of cellular functions (Feist et al., ). The synthesis and interconversion of these metabolites is made possible by the catalytic activities of countless enzymes. By lowering the activation energy barrier, enzymes catalyze reactions at considerably faster rates than their chemical counterparts. This characteristic property along with the relatively high degree of substrate selectivity, permit the use of enzymes as catalysts for industrial purposes. For those enzymes, which rely solely on amino acids for catalysis, the types of reactions are extremely narrow in scope and, for the most part, restricted to acid/base and electrophilic/nucleophilic reactions (Broderick, ). To further extend, the range of reactions, enzymes are commonly associated with non-protein moieties known as cofactors (Broderick, ).
In the broadest sense of the term, cofactors are thought to be associated with well over half of known proteins (Fischer et al., ). However, for this article, the term “cofactor” will refer specifically to those moieties, either organic or inorganic, which remain physically associated with the enzyme throughout the catalytic cycle (Fischer et al., ). This excludes dissociable cosubstrates such as NADPH and glutathione. Additionally, since the primary focus of this article is on pathway engineering, only those cofactors that require de novo pathways for syntheses will be mentioned and sole metal entities such as calcium and selenium will also be excluded. Using this strict definition, a selection of common cofactors are listed in Table 1. These are categorized into two types: organic and inorganic (Rees, ; Fischer et al., ). Members of the organic group of cofactors tend to be derivatives of vitamins and undertake numerous types of reactions, while the inorganic group is usually based on various arrangements of iron–sulfur (Fe–S) clusters.
Table 1
| Enzyme bound cofactor | Type of reaction catalyzed | Example of a cofactor-containing enzyme | Associated pathway |
|---|---|---|---|
| ORGANIC COFACTORS | |||
| Biotin | Carbon dioxide addition | Acetyl CoA carboxylase | Fatty acid biosynthesis |
| Factor F430 | Methyl transfer | Methyl coenzyme M reductase | Methanogenesis |
| Flavin mononucleotide | Electron transfer | Cytochrome P450 reductase | Detoxification |
| Heme | Electron transfer | Cytochrome P450 | Detoxification |
| Lipoic acid | Acyl/methyl amine transfer | 2-oxoacid dehydrogenase | Citric acid cycle |
| MIO cofactor | Carbon–hydrogen bond activation | Phenylalanine ammonia-lyase | Polyphenol biosynthesis |
| Molybdopterin | Electron transfer | Xanthine oxidase | Purine catabolism |
| Phosphopantetheine | Acyl carrier | Carboxylic acid reductase | Fatty acid metabolism |
| Pyridoxal 5′phosphate | Transamination | Glycogen phosphorylase | Glycogenosis |
| Pyrroloquinoline quinone | Electron transfer | Methanol dehydrogenase | Methane metabolism |
| Thiamine pyrophosphate | Carbon dioxide removal | Pyruvate ferredoxin/flavodoxin reductase | Pyruvate decarboxylation |
| Topaquinone | Amine oxidation | Amine oxidase | Urea cycle |
| INORGANIC COFACTORS | |||
| Fe–S | Electron transfer | Ferredoxin | Iron–sulfur cluster biogenesis |
| H-cluster | Hydrogen activation | Fe–Fe hydrogenase | Hydrogen metabolism |
| Fe-Moco | Nitrogen reduction | Nitrogenase | Nitrogen fixation |
| C-cluster | Carbon monoxide oxidation | Carbon monoxide dehydrogenase | Carbon monoxide metabolism |
| P-cluster | Electron transfer | Nitrogenase | Nitrogen fixation |
Examples of enzyme bound cofactors.
For a more comprehensive list of organic cofactors refer Fischer et al. ().
In its cofactor-bound state, enzymes are referred to as holoenzymes while in the unbound state, they are known as apoenzymes (Figure 1A). Two discrete structural parts are required for the synthesis of a holoenzyme: a polypeptide chain and a cofactor moiety. The former is generated by the ubiquitous translational machinery while the latter, depending upon the cofactor, is synthesized by a defined metabolic pathway. In certain cases, subtle variations of the cofactor pathway may exist. For example, in animals, fungi, and α-proteobacteria, heme synthesis is initiated by 5-aminolevulinate synthase, via condensation of glycine and succinyl CoA, while in photosynthetic eukaryotes and some species of the α-proteobacterial group, it depends on glutamate, via the concerted actions of three enzymes (Layer et al., ). Once synthesized, the cofactor is integrated with the apoenzyme, either in a co-translational or post-translational manner, to form the holoenzyme. The nature of the association may be covalent and, in such cases, linkages are typically formed with serine, threonine, histidine, tyrosine, and lysine residues and catalyzed by a distinct maturation system. As an example, the heme c in cytochrome c is attached to a cysteine residue, via the vinyl group with the aid of Ccm (cytochrome c maturation) factors (Sanders et al., ). Alternatively, the interaction may be tight but non-covalent as in the case of the flavin-containing enzyme, acyl CoA dehydrogenase (Thorpe and Kim, ).
Figure 1
Importance of Cofactor Synthesis for Both Enzyme and Pathway Functionality
As integral components of numerous holoenzymes, cofactors are required for the majority of metabolic pathways. To name but a few, these include: FAD in succinate dehydrogenase for the Krebs cycle; TPP in transketolase for the pentose phosphate pathway; pyridoxal phosphate in glycogen phosphorylase for glycogenolysis; H-clusters in hydrogenases for hydrogen metabolism; Fe–MoCo in nitrogenases for nitrogen fixation; biotin in acetyl CoA carboxylase for fatty acid biosynthesis; and haem in cytochrome P450 for various detoxification pathways. The most crucial point to consider is that the functional output of holoenzymes can only arise if the apoenzyme is correctly folded with its cofactor. Without the cofactor, such enzymes would be rendered inoperable and the associated pathways would become redundant. This situation, though undesirable, is likely to be encountered in a bottom-up approach to microbial engineering in which a genetically amenable and well-characterized organism, such as Escherichia coli and Saccharomyces cerevisiae may be completely devoid of cofactors necessary for heterologous enzyme activity. Alternatively, the capability of the host to synthesize the required cofactor exists but may be insufficient, resulting in a pool of enzymes with a high ratio of apo to holo form (see next section). The most obvious strategy for resolving these issues would be to resort to “cofactor engineering,” by genetically modifying the host so that the cofactor assembly system is present or that the level of native cofactor assembly is in sufficient supply.
Consider the expression of the clostridial Fe–Fe hydrogenase. This enzyme depends on an H-cluster that essentially is a di-iron arrangement with three carbon monoxide, two cyanide ligands, and one dithiolate bridge (Mulder et al.,
Cofactor Insertion is Key to Maximizing Total and Specific Holoenzyme Activity
To maximize the specific activity of a holoenzyme, cofactor synthesis would need to be complemented and/or coupled with cofactor insertion. For enzymes, which bind to cofactors in a non-covalent fashion, the process of cofactor insertion is somewhat of an enigma. It is still not known, even for the well-known heme b cofactor, whether this process is facilitated by dedicated in vivo components or is a spontaneous process (Thöny-Meyer,
In addition to stimulating the specific enzyme activity, increasing the intracellular levels of cofactors is also known to improve the overall production levels of holoenzymes, suggesting a relationship between holo/apo-forms and degradation. This is a phenomenon that has been frequently observed for hemoproteins (Harnastai et al.,
Stimulating Cofactor Synthesis Can Enhance the Flux of Synthetic Pathways
With regard to the actual impact that cofactor engineering can have on the metabolic performance of synthetic pathways, two studies are particularly worthy of mention. In the first study relating to the production of the vitamin C precursor, 2-keto-l-gulonic acid, Gao et al. (
The second study relates to a synthetic pathway for hydrogen production consisting of a pyruvate:ferredoxin oxidoreductase (PFOR, also known as YdbK in the literature), Fdx and Fe–Fe hydrogenase (Akhtar and Jones,
Although cofactor biosynthesis and integration under native control can be limiting and unresponsive to high-expression levels of the apoform, presumably to conserve cellular resources, cofactor engineering can quite clearly be advantageous for the assembly of metabolic pathways that depend on the activity of heterologous holoenzymes. This benefit presumably arises from the improved holoenzyme activity, via increased structural stability and/or folding rates in conjunction with reduced protein degradation and/or protein unfolding (explained in the previous section). Interestingly, data from our work on the in vitro activity of Fe–S proteins also suggests that, under certain conditions, a steady and constant supply of cofactors may well aid the restoration of damaged or inactivated enzymes (Akhtar and Jones,
Concluding Remarks
Achieving a balanced production of polypeptide and cofactor for optimal holoenzyme activity would be an iterative process involving the (i) modulated induction of genes, (ii) monitoring of cofactor levels, (iii) evaluation of enzyme activity, and (iv) evaluation of whole-system productivity. Genetic modulation can be controlled at the transcriptional and translational levels by varying the strengths of promoter and ribosomal binding sites, while cofactor levels can be monitored and quantified using suitable analytical methods, e.g., mass spectrometry, high-performance liquid chromatography (HPLC). Combining this with information relating to specific enzyme activity should allow provide profound insights into the intracellular cofactor levels required to achieve optimal holoenzyme activity. Furthermore, if a product reporter system is available, it may also be possible to screen for optimal cofactor metabolism, for example using RBS-variation libraries (Zelcbuch et al.,
Given the importance of cofactor synthesis and integration for holoenzyme activity, a few key points need to be considered when assembling pathways involving holoenzymes. Firstly, holoenzyme activity will only be possible within a host that is metabolically equipped to synthesize the necessary cofactor, otherwise a complementary pathway for cofactor production would also need to be implemented. This is particularly relevant for synthetic pathways that employ holoenzymes from diverse origins. Secondly, to ensure maximal activity of the holoenzyme, the apoenzyme needs to be sufficiently coupled with the synthesis and insertion of its respective cofactor. An imbalance between the two will lead to poor enzyme activity, one that would most likely be inadequate for catalytic purposes. Even native cofactor biosynthesis may not be optimally tuned or responsive to demand from an over-expressed apoenzyme, as would be required in a biocatalytic system where the objective function has shifted from biomass to metabolite producer. Thirdly, since cofactor stimulation is known to improve the stability and activity of holoenzymes, cofactor engineering is likely to be a useful strategy for enhancing the total activity of all holoenzymes in the engineered pathway, and maximizing chances for high flux toward the product of interest. As it currently stands, the impact of cofactor engineering on the activity of holoenzymes is still very much a poorly studied area and certainly warrants more attention given its potential impact on the success of engineered biocatalytic systems.
Statements
Acknowledgments
This work that spurred our views, reflected within this perspective, was supported in part by the Academy of Finland project no. 25369 and European Research Council under the European Union’s Seventh Framework Programme (FP7/2007-2013)/European Research Council Grant Agreement 260661 (Patrik R. Jones).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AkhtarM.JonesP. (2008a). Deletion of iscR stimulates recombinant clostridial Fe-Fe hydrogenase activity and H2-accumulation in Escherichia coli BL21(DE3). Appl. Microbiol. Biotechnol.78, 853–862.10.1007/s00253-008-1377-6
2
AkhtarM.JonesP. (2008b). Engineering of a synthetic hydF-hydE-hydG-hydA operon for biohydrogen production. Anal. Biochem.373, 170–172.10.1016/j.ab.2007.10.018
3
AkhtarM.JonesP. (2009). Construction of a synthetic YdbK-dependent pyruvate: H2 pathway in Escherichia coli BL21(DE3). Metab. Eng.11, 139–147.10.1016/j.ymben.2009.01.002
4
AkhtarM. K.TurnerN. J.JonesP. R. (2013). Carboxylic acid reductase is a versatile enzyme for the conversion of fatty acids into fuels and chemical commodities. Proc. Natl. Acad. Sci. U.S.A.110, 87–92.10.1073/pnas.1216516110
5
BroderickJ. B. (2001). Coenzyme and Cofactors. eLS.
6
BushmarinaN. A.BlanchetC. E.VernierG.ForgeV. (2006). Cofactor effects on the protein folding reaction: acceleration of alpha-lactalbumin refolding by metal ions. Protein Sci.15, 659–671.10.1110/ps.051904206
7
ChurchG. M.ElowitzM. B.SmolkeC. D.VoigtC. A.WeissR. (2014). Realizing the potential of synthetic biology. Nat. Rev. Mol. Cell Biol.15, 289–294.10.1038/nrm3767
8
CorreiaM. A.SinclairP. R.De MatteisF. (2011). Cytochrome P450 regulation: the interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal. Drug Metab. Rev.43, 1–26.10.3109/03602532.2010.515222
9
FeistA.HerrgårdM.ThieleI.ReedJ.PalssonB. (2009). Reconstruction of biochemical networks in microorganisms. Nat. Rev. Microbiol.7, 129–143.10.1038/nrmicro1949
10
FischerJ. D.HollidayG. L.RahmanS. A.ThorntonJ. M. (2010a). The structures and physicochemical properties of organic cofactors in biocatalysis. J. Mol. Biol.403, 803–824.10.1016/j.jmb.2010.09.018
11
FischerJ. D.HollidayG. L.ThorntonJ. M. (2010b). The CoFactor database: organic cofactors in enzyme catalysis. Bioinformatics26, 2496–2497.10.1093/bioinformatics/btq442
12
FontecaveM.ChoudensS. O.PyB.BarrasF. (2005). Mechanisms of iron-sulfur cluster assembly: the SUF machinery. J. Biol. Inorg. Chem.10, 713–721.10.1007/s00775-005-0025-1
13
GallagherJ.KaderbhaiN.KaderbhaiM. A. (1992). Gene-dose-dependent expression of soluble mammalian cytochrome b5 in Escherichia coli. Appl. Microbiol. Biotechnol.38, 77–83.10.1007/BF00169423
14
GaoL.DuG.ZhouJ.ChenJ.LiuJ. (2013). Characterization of a group of pyrroloquinoline quinone-dependent dehydrogenases that are involved in the conversion of l-sorbose to 2-Keto-l-gulonic acid in Ketogulonicigenium vulgare WSH-001. Biotechnol. Prog.29, 1398–1404.10.1002/btpr.1803
15
GaoL.HuY.LiuJ.DuG.ZhouJ.ChenJ. (2014). Stepwise metabolic engineering of gluconobacter oxydans WSH-003 for the direct production of 2-keto-l-gulonic acid from d-sorbitol. Metab. Eng.24, 30–37.10.1016/j.ymben.2014.04.003
16
GoedkenE. R.KeckJ. L.BergerJ. M.MarquseeS. (2000). Divalent metal cofactor binding in the kinetic folding trajectory of Escherichia coli ribonuclease HI. Protein Sci.9, 1914–1921.10.1110/ps.9.10.1914
17
GuterlJ. K.GarbeD.CarstenJ.StefflerF.SommerB.ReisseS.et al (2012). Cell-free metabolic engineering: production of chemicals by minimized reaction cascades. ChemSusChem5, 2165–2172.10.1002/cssc.201200365
18
HarnastaiI. N.GilepA. A.UsanovS. A. (2006). The development of an efficient system for heterologous expression of cytochrome P450s in Escherichia coli using hemA gene co-expression. Protein Expr. Purif. 46, 47–55.10.1016/j.pep.2005.07.006
19
KeaslingJ. D. (2010). Manufacturing molecules through metabolic engineering. Science330, 1355–1358.10.1126/science.1193990
20
LayerG.ReicheltJ.JahnD.HeinzD. W. (2010). Structure and function of enzymes in heme biosynthesis. Protein Sci.19, 1137–1161.10.1002/pro.405
21
LiuL.MartinezJ. L.LiuZ.PetranovicD.NielsenJ. (2014). Balanced globin protein expression and heme biosynthesis improve production of human hemoglobin in Saccharomyces cerevisiae. Metab. Eng.21, 9–16.10.1016/j.ymben.2013.10.010
22
LuH.MaJ.LiuN.WangS. (2010). Effects of heme precursors on CYP1A2 and POR expression in the baculovirus/Spodoptera frugiperda system. J. Biomed. Res.24, 242–249.10.1016/S1674-8301(10)60034-6
23
LuH. Y.QiuL. L.YangX. J.ZhangX. M.ZhangZ.WangS. L. (2013). Optimization of heme precursors for the expression of human cytochrome P450 2A13 and its co-expression with oxidoreductase in baculovirus/sf9 system. J. Biochem.153, 555–563.10.1093/jb/mvt018
24
MatsushitaK.ArentsJ. C.BaderR.YamadaM.AdachiO.PostmaP. W. (1997). Escherichia coli is unable to produce pyrroloquinoline quinone (PQQ). Microbiology143, 3149–3156.10.1099/00221287-143-10-3149
25
MatsushitaK.ToyamaH.YamadaM.AdachiO. (2002). Quinoproteins: structure, function, and biotechnological applications. Appl. Microbiol. Biotechnol.58, 13–22.10.1007/s00253-001-0851-1
26
MichenerJ. K.NielsenJ.SmolkeC. D. (2012). Identification and treatment of heme depletion attributed to overexpression of a lineage of evolved P450 monooxygenases. Proc. Natl. Acad. Sci. U.S.A.109, 19504–19509.10.1073/pnas.1212287109
27
MulderD. W.ShepardE. M.MeuserJ. E.JoshiN.KingP. W.PosewitzM. C.et al (2011). Insights into [FeFe]-hydrogenase structure, mechanism, and maturation. Structure19, 1038–1052.10.1016/j.str.2011.06.008
28
NakamuraM.SaekiK.TakahashiY. (1999). Hyperproduction of recombinant ferredoxins in Escherichia coli by coexpression of the ORF1-ORF2-iscS-iscU-iscA-hscB-hs cA-fdx-ORF3 gene cluster. J. Biochem.126, 10–18.10.1093/oxfordjournals.jbchem.a022409
29
Palm-EsplingM. E.NiemiecM. S.Wittung-StafshedeP. (2012). Role of metal in folding and stability of copper proteins in vitro. Biochim. Biophys. Acta1823, 1594–1603.10.1016/j.bbamcr.2012.01.013
30
Perez-DuenasB.VilasecaM. A.MasA.LambruschiniN.ArtuchR.GomezL.et al (2004). Tetrahydrobiopterin responsiveness in patients with phenylketonuria. Clin. Biochem.37, 1083–1090.10.1016/j.clinbiochem.2004.09.005
31
PosewitzM. C.KingP. W.SmolinskiS. L.ZhangL.SeibertM.GhirardiM. L. (2004). Discovery of two novel radical S-adenosylmethionine proteins required for the assembly of an active [Fe] hydrogenase. J. Biol. Chem.279, 25711–25720.10.1074/jbc.M403206200
32
ReesD. C. (2002). Great metalloclusters in enzymology. Annu. Rev. Biochem.71, 221–246.10.1146/annurev.biochem.71.110601.135406
33
ReydaM. R.DippoldR.DotsonM. E.JarrettJ. T. (2008). Loss of iron-sulfur clusters from biotin synthase as a result of catalysis promotes unfolding and degradation. Arch. Biochem. Biophys.471, 32–41.10.1016/j.abb.2007.12.001
34
RocheB.AusselL.EzratyB.MandinP.PyB.BarrasF. (2013). Iron/sulfur proteins biogenesis in prokaryotes: formation, regulation and diversity. Biochim. Biophys. Acta1827, 455–469.10.1016/j.bbabio.2012.12.010
35
SandersC.TurkarslanS.LeeD. W.DaldalF. (2010). Cytochrome c biogenesis: the Ccm system. Trends Microbiol.18, 266–274.10.1016/j.tim.2010.03.006
36
StephanopoulosG. (2012). Synthetic biology and metabolic engineering. ACS Synth. Biol.1, 514–525.10.1021/sb300094q
37
Thöny-MeyerL. (2009). “Heme transport and incorporation into proteins,” in Tetrapyrroles: Birth, Life and Death, eds WarrenM. J.SmithA. G. (Landes Bioscience and Springer Science+Business Media), 149–159.
38
ThorpeC.KimJ. J. (1995). Structure and mechanism of action of the acyl-CoA dehydrogenases. FASEB J.9, 718–725.
39
VeitA.AkhtarM.MizutaniT.JonesP. (2008). Constructing and testing the thermodynamic limits of synthetic NAD(P)H:H2 pathways. Microb. Biotechnol.1, 382–394.10.1111/j.1751-7915.2008.00033.x
40
VenkitasubramanianP.DanielsL.RosazzaJ. P. (2007). Reduction of carboxylic acids by Nocardia aldehyde oxidoreductase requires a phosphopantetheinylated enzyme. J. Biol. Chem.282, 478–485.10.1074/jbc.M607980200
41
WaheedS. M.GhoshA.ChakravartiR.BiswasA.HaqueM. M.PandaK.et al (2010). Nitric oxide blocks cellular heme insertion into a broad range of heme proteins. Free Radic. Biol. Med.48, 1548–1558.10.1016/j.freeradbiomed.2010.02.038
42
WilsonC. J.ApiyoD.Wittung-StafshedeP. (2004). Role of cofactors in metalloprotein folding. Q. Rev. Biophys.37, 285–314.10.1017/S003358350500404X
43
Wittung-StafshedeP. (2002). Role of cofactors in protein folding. Acc. Chem. Res.35, 201–208.10.1021/ar010106e
44
YamamotoK.KataokaE.MiyamotoN.FurukawaK.OhsuyeK.YabutaM. (2003). Genetic engineering of Escherichia coli for production of tetrahydrobiopterin. Metab. Eng.5, 246–254.10.1016/S1096-7176(03)00046-6
45
YangX. P.ZhongG. F.LinJ. P.MaoD. B.WeiD. Z. (2010). Pyrroloquinoline quinone biosynthesis in Escherichia coli through expression of the gluconobacter oxydans pqqABCDE gene cluster. J. Ind. Microbiol. Biotechnol.37, 575–580.10.1007/s10295-010-0703-z
46
ZelcbuchL.AntonovskyN.Bar-EvenA.Levin-KarpA.BarenholzU.DayagiM.et al (2013). Spanning high-dimensional expression space using ribosome-binding site combinatorics. Nucl. Acids Res.41:e98.10.1093/nar/gkt151
Summary
Keywords
cofactors, metabolic pathway engineering, Fe–S clusters, enzymatic activity, synthetic biology
Citation
Akhtar MK and Jones PR (2014) Cofactor Engineering for Enhancing the Flux of Metabolic Pathways. Front. Bioeng. Biotechnol. 2:30. doi: 10.3389/fbioe.2014.00030
Received
12 June 2014
Accepted
12 August 2014
Published
28 August 2014
Volume
2 - 2014
Edited by
Pablo Carbonell, University of Evry, France
Reviewed by
Juan Manuel Pedraza, Universidad de los Andes, Colombia; Gary Sawers, Martin-Luther University Halle-Wittenberg, Germany
Copyright
© 2014 Akhtar and Jones.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: M. Kalim Akhtar, Department of Biochemical Engineering, University College London, Torrington Place, London, WC1E 7JE, UK e-mail: kalim.akhtar@ucl.ac.uk; Patrik R. Jones, Department of Life Sciences, Imperial College London, Sir Alexander Fleming building, London, SW7 2AZ, UK e-mail: p.jones@imperial.ac.uk
This article was submitted to Synthetic Biology, a section of the journal Frontiers in Bioengineering and Biotechnology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.